Dynavax Technologies Corporation (NASDAQ:DVAX) PT Set at $7.00 by Royal Bank Of Canada

Royal Bank Of Canada set a $7.00 price target on Dynavax Technologies Corporation (NASDAQ:DVAX) in a research report sent to investors on Wednesday, July 26th. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a hold rating to a buy rating and set a $11.00 price objective on the stock in a research report on Monday, July 10th. ValuEngine downgraded shares of Dynavax Technologies Corporation from a sell rating to a strong sell rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $23.34.

Dynavax Technologies Corporation (DVAX) traded up 2.623% during trading on Wednesday, hitting $16.625. The stock had a trading volume of 1,706,799 shares. The firm has a 50 day moving average price of $12.06 and a 200-day moving average price of $7.35. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $19.60. The firm’s market capitalization is $910.17 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.09. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same quarter in the prior year, the firm earned ($0.75) earnings per share. On average, equities research analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/dynavax-technologies-corporation-nasdaqdvax-given-a-7-00-price-target-by-royal-bank-of-canada-analysts-updated-updated/1309357.html.

Several hedge funds have recently made changes to their positions in DVAX. Parametric Portfolio Associates LLC boosted its stake in shares of Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 939 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Dynavax Technologies Corporation by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 176,996 shares of the biopharmaceutical company’s stock worth $1,053,000 after buying an additional 6,623 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Dynavax Technologies Corporation during the first quarter worth about $121,000. Falcon Point Capital LLC boosted its stake in shares of Dynavax Technologies Corporation by 57.5% in the first quarter. Falcon Point Capital LLC now owns 117,568 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 42,929 shares during the period. Finally, C WorldWide Group Holding A S boosted its stake in shares of Dynavax Technologies Corporation by 8.1% in the first quarter. C WorldWide Group Holding A S now owns 284,082 shares of the biopharmaceutical company’s stock worth $1,690,000 after buying an additional 21,313 shares during the period. 57.49% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.